Share >  
Share
Share on Tumblr

Axicorp

News »

   latest by relevance
Espirito Santo questions Biocon's accounting practices
May 22, 2012 at 10:15 | Source: Moneycontrol.com
Espirito Santo has downgraded Bangalore-based Biocon to "sell" from "neutral" and sharply revised its target price to Rs 186 a share from Rs 350, flagging off several issues, which it says raise accounting and corporate governance questions over at the biotech firm.
Biocon Q2 net drops as energy costs, wages rise
Oct 20, 2011 at 11:15 | Source: Reuters
Biocon Ltd, India top biotechnology company, reported a 4% drop in quarterly profit due to higher energy costs and rise in wages, but said strong demand from branded formulations offered opportunities for growth.
Biocon Q1 net down 9% to Rs 70 crore, shares fall
Jul 21, 2011 at 09:41 | Source: Moneycontrol.com
Biotechnology company Biocon's consolidated net profit for the first quarter fell almost 9% from a year ago to Rs 70.05 crore, while net sales were up over 10% to Rs 441.68 crore.
Pfizer partnership to give Biocon strong foothold in Europe
Apr 28, 2011 at 23:00 | Source: CNBC-TV18
This quarter Biocon's net profit has risen 25% from the same period last year to 101 crore rupees, meeting analyst estimates and to keep this growth going, Biocon is shedding the fat, reports CNBC-TV18's Vineetha Athrey.
Biocon Q4 net up 25%, divests stake in German unit
Apr 28, 2011 at 11:52 | Source: Reuters
India's largest listed biotechnology firm Biocon said on Thursday it would divest its stake in German unit AxiCorp, after roughly meeting estimates with a 25% rise in the fourth-quarter net profit.
Axicorp to contribute to PAT in 18-24 months: Biocon
Jul 23, 2009 at 12:17 | Source: Moneycontrol.com
Biocon has declared its first quarter results. The company's consolidated net sales were up 86% at Rs 496 crore versus Rs 263.9 crore.

Videos »
Biocon Q1 net down 9% to Rs 70 crore, shares fall
Pfizer partnership to give Biocon strong foothold in Europe
Biocon Q4 net up 25%, divests stake in German unit
Biocon sees no MTM losses going forward
more »

Photos »

  /  
News across the web »
I-bank Espirito Santo concerned at Biocon's accounting processesBiotech company denies all charges
Portuguese investment bank Espirito Santo has raised concerns over the accounting processes of Bangalore-based biotechnology company Biocon. In a report released to the investment community on Monday,...
May 22, 2012 at 00:51 | Source: Business Standard
Biocon beats estimates but net down 3%
Biotechnology company Biocon on Friday reported a 2.98 per cent drop in its fourth-quarter consolidated net profit at Rs 97.8 crore, compared to the corresponding quarter in the previous year, but bea...
Apr 28, 2012 at 01:56 | Source: Business Standard
$350-mn Pfizer-Biocon pact offBiocon stock hits 52-week low, company still likely to get $150-170 mn
India s largest bio-pharmaceutical company, Biocon, suffered a severe jolt on Tuesday, as its $350-million pact with global pharmaceutical major Pfizer was called off, hardly 18 months after the deal ...
Mar 14, 2012 at 04:46 | Source: Business Standard
Biocon's long-term growth hinges on new alliances
March 13, 2012: After a courtship period of one and half year, Pfizer and Biocon have parted ways, citing differences in “individual priorities”. While break ups are never easy, the Pfize...
Mar 14, 2012 at 03:08 | Source: The Hindu BusinessLine
Biocon's profit declines 14% in Q3
Biocon’s profit has declined by 14 per cent to Rs 85 crore for the third quarter (Q3) ended December 31, 2011 against Rs 99 crore in the corresponding period last fiscal. However, the biotech m...
Jan 25, 2012 at 10:42 | Source: The Hindu BusinessLine
more »
Interact & exchange stock tips & market info »

stocktin

Silver Member

1 Followers

Biocon  

on that break up to justify the price target. if people who bought o...

6.25 PM May 21st

Guest

Biocon  

aspirations” or “This, alongwith use of a creative transaction st...

4.51 PM May 21st

sadharanan

Silver Member

1 Followers

Biocon  

years to net off against trial costs.Smoothening out of R&D costs to ...

2.07 PM May 21st

Related News »
I-bank Espirito Santo concerned at Biocon's accounting processes
In a report released to the investment community on Monday, the Lisbon-based financial group has asked questions related to Biocon’s accounting, mainly during its split with Pfizer on the $350-million insulin deal and its divestment of stake in AxiCorp.
May 21, 2012 at 19:07 | Source: Business Standard
Opening bell 22 May | Markets on firmer footing
Espirito Santo in report released to investment community said that Biocon had booked a notional loss of euro 21 million in the AxiCorp deal and did not factor in $200-million upfront milestone payment it received from Pfizer in its Profit & Loss account.
May 22, 2012 at 02:38 | Source: Livemint.com

Follow moneycontrol.com

Facebook Twitter Google Plus RSS Wap SMS SMS Alert iPad iPhone Blackberry OVI Android Window